Trial Profile
A Multiple Dose, Two-cohort Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous LFG316 in Patients With Neovascular Age-related Macular Degeneration
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2020
Price :
$35
*
At a glance
- Drugs Tesidolumab (Primary)
- Indications Age-related macular degeneration
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 02 Dec 2014 New trial record